Cargando…

Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects

AIM: Incretins [dipeptidyl peptidase-4 inhibitors (DPP-4i) and glucagon-like peptide 1 RA (GLP-1 RA)] and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) groups are now routinely used for type 2 diabetes therapy and comprise a large number of medicinal products. The long term therapeutic and eco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitkova, Zornitsa, Mitov, Konstantin, Valov, Vasil, Manova, Manoela, Savova, Alexandra, Kamusheva, Maria, Tcharaktchiev, Dimitar, Angelov, Zhivko, Angelova, Galia, Petrova, Guenka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477021/ https://www.ncbi.nlm.nih.gov/pubmed/31040779 http://dx.doi.org/10.3389/fphar.2019.00364

Ejemplares similares

Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2020)

New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria
por: Kamusheva, Maria, et al.
Publicado: (2020)

Comparison of Cardiovascular Medicines Prices in Four European Countries
por: Mitkova, Zornitsa, et al.
Publicado: (2020)

Аn affordability of statins therapy - comparative analysis between Ukraine and Bulgaria
por: Tkachova, Oksana, et al.
Publicado: (2019)

Budget cap and pay-back model to control spending on medicines: A case study of Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
por: Russel-Szymczyk, Monika, et al.
Publicado: (2019)

Pharmacotherapeutic Patterns and Patients’ Access to Pharmacotherapy for Some Rare Diseases in Bulgaria – A Pilot Comparative Study
por: Kamusheva, Maria, et al.
Publicado: (2021)

Review of medicine utilization for Parkinson’s disease management: The Bulgarian perspective
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
por: Manova, Manoela, et al.
Publicado: (2018)

Analysis of Healthcare Expenditures in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2022)

Utilization, Cost, and Affordability of Antihypertensive Therapy in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

Analysis of the Household and Health Care System Expenditures in Bulgaria
por: Mitkova, Zornitsa, et al.
Publicado: (2021)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

Biosimilar Insulins and Their Impact on Prices and Utilization of Insulins in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care
por: Kamusheva, Maria, et al.
Publicado: (2021)

Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting
por: Dimitrova, Maria, et al.
Publicado: (2014)

Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2019)

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

How Managed Entry Agreements Influence the Patients’ Affordability to Biological Medicines—Bulgarian Example
por: Mitkova, Zornitsa, et al.
Publicado: (2023)

Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
por: Boyadzieva, Vladimira V., et al.
Publicado: (2018)

Treatment patterns, adherence to international guidelines, and financial mechanisms of the market access of advanced breast cancer therapy in Bulgaria
por: Karanyotova, Stephanie, et al.
Publicado: (2023)

Study of Symptom Severity and Adherence to Therapy of Myelofibrosis Patients Treated with Ruxolitinib
por: Stoeva, Vera, et al.
Publicado: (2023)

Adherence to Acromegaly Treatment and Analysis of the Related Factors—A Real-World Study in Bulgaria
por: Kamusheva, Maria, et al.
Publicado: (2023)

Evaluation of potentially inappropriate medication in older patients with cardiovascular diseases—STOPP/START-based study
por: Krustev, Tzvetan, et al.
Publicado: (2022)

Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal Study
por: Stoeva, Vera, et al.
Publicado: (2023)

Chronic Hepatitis C-Related Cirrhosis Hospitalization Cost Analysis in Bulgaria
por: Dimitrova, Maria, et al.
Publicado: (2017)

Recommendations for patient involvement in health technology assessment in Central and Eastern European countries
por: Jakab, Ivett, et al.
Publicado: (2023)

Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy
por: Petrova, Guenka, et al.
Publicado: (2017)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review
por: Kawalec, Paweł, et al.
Publicado: (2017)

Potential Barriers of Patient Involvement in Health Technology Assessment in Central and Eastern European Countries
por: Dimitrova, Maria, et al.
Publicado: (2022)

The Evolution of Diabetes Treatment Through the Ages: From Starvation Diets to Insulin, Incretins, SGLT2-Inhibitors and Beyond
por: Mudaliar, Sunder
Publicado: (2023)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Barriers to Use Artificial Intelligence Methodologies in Health Technology Assessment in Central and East European Countries
por: Tachkov, Konstantin, et al.
Publicado: (2022)

Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment
por: Zemplényi, Antal, et al.
Publicado: (2023)

Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland
por: Kamusheva, Maria, et al.
Publicado: (2021)

Liquid Crystalline Nanostructures as PEGylated Reservoirs of Omega-3 Polyunsaturated Fatty Acids: Structural Insights toward Delivery Formulations against Neurodegenerative Disorders
por: Angelova, Angelina, et al.
Publicado: (2018)

Na(+)-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion
por: Gorboulev, Valentin, et al.
Publicado: (2012)

Humanistic and economic aspects of haemophilia treatment in Bulgaria. Comparison between two therapeutic approaches: prophylactic vs. on-demand treatment
por: Petrova, Guenka, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_l1k3l3nnepgigovnuivgj1o2u6